Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Q3 2026 Earnings Presentation
39 slides from Lumos Diagnostics's earnings presentation, Apr 21, 2026
Slide 1: Lumos Diagnostics Holdings Limited Investor Presentation
For personal use only Lumos Diagnostics Holdings Limited Investor Presentation 21 April 2026 The consolidated entity’s presentation currency is US Dollars. Financial information is shown in USD unless otherwise stated. Placement, Share Purchase Plan and Share Price information is shown in AUD, as th
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (“Presentation”) has been prepared by Lumos Diagnostics Holdings Limited (ABN 66 630 476 970) (“Lumos” or “Company”) solely for informational purposes in connection with its proposed non-underwritten institutional placement of new fully paid ord
Slide 3: Disclaimer and Important Information
Disclaimer and Important Information Forward Looking Statements None of the Limited Parties or the JLM Parties (as defined below) makes or gives any representation, warranty or guarantee, express or implied, that the Presentation, or the information, assumptions, opinions and For personal use only c
Slide 4: Disclaimer and Important Information
Disclaimer and Important Information Not for distribution or release in the United States The distribution of this Presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this Presentation who are not in Australia, should observe any such restric
Slide 5: Disclaimer and Important Information
Disclaimer and Important Information Disclaimer MST Financial Services Pty Limited (ABN 54 617 475 180), Barrenjoey Markets Pty Limited (ABN 66 636 976 059) and Foster Stockbroking Pty Limited (ABN 15 088 747 148) (together, the “Joint Lead Managers”) For personal use only are acting as joint lead m
Slide 6: Disclaimer and Important Information
Disclaimer and Important Information In connection with the Placement, one or more investors may elect to acquire an economic interest in the New Shares (“Economic Interest”), instead of subscribing for or acquiring the legal or beneficial interest in those securities. A member of the JLM Group may,
Slide 7: Introduction to Lumos Diagnostics
Introduction to Lumos Diagnostics Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care For personal use only FebriDx® CLIA waiver increases FebriDx® received 510k TAM from 18k sites and ~6m US$317m (A$487m
Slide 8: Highly experienced board and management team
Highly experienced board and management team The Lumos board and management team have a proven track record in commercialisation of medical diagnostics at various global healthcare companies For personal use only Sam Lanyon Bronwyn Le Grice Lawrence Mehren Catherine Robson Doug Ward Barrie Lambert S
Slide 9: The respiratory infection testing problem
The respiratory infection testing problem It is difficult to distinguish between viral and bacterial infections as they present similar symptoms, leading doctors to overprescribe antibiotics as a precautionary measure rather than a targeted treatment For personal use only The respiratory infection t
Slide 10: Our solution: FebriDx, a simple microbial infection test
Our solution: FebriDx® | a simple microbial infection test FebriDx® can rapidly identify patients who have a microbial infection1 and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes For personal use only What is FebriDx®? What has it achieved?2 F
Slide 11: FebriDx IP
FebriDx® IP Our FebriDx® licensing / IP agreements add recurring high-margin revenue For personal use only R On-strip cell lysis Lumos FebriDx Patents • Blood cell lysis chemical formulation • 59 FebriDx patents, 4 patent families • Detection of intracellular and extracellular • 17 countries biomark
Slide 12: Acute respiratory infection – patient clinical pathway
Acute respiratory infection – patient clinical pathway For personal use only Patient Triage Doctor Treatment Billing Check-In Testing Decision Covid/Flu FebriDx © Lumos Diagnostics . All rights reserved. 12
Slide 13: The FebriDx market opportunity grows with CLIA waiver
The FebriDx® market opportunity grows with CLIA waiver The CLIA waiver grant expands the US customer sites by enabling facilities (e.g. physician offices and stand-alone urgent care centres) to perform diagnostics without laboratory oversight For personal use only Moderate complexity + CLIA waiver =
Slide 14: CLIA waiver expands our commercialisation options
CLIA waiver expands our commercialisation options The two key US market opportunities for testing are in urgent care and primary care sites; these have formed our target sites as we continue commercialisation of FebriDx® For personal use only US market opportunities in acute respiratory infection te
Slide 15: The path to commercial adoption
The path to commercial adoption Lumos’ approach to commercialisation is founded on three critical pillars For personal use only #1 #2 #3 Clinical Benefit Economic Benefit Operational Efficiency Only test that distinguishes between Reimbursed under PLA code at $41.38 per Easily integrated alongside C
Slide 16: There is a whole value chain accessible post CLIA waiver
There is a whole value chain accessible post CLIA waiver The in vitro diagnostics (IVD) value chain and economic flow is summarised below For personal use only 1 2 3 4 Healthcare providers / Manufacturers Distributors Payers physicians Sales to healthcare providers, R&D and production of IVD Utilise
Slide 17: PHASE Scientific Exclusive FebriDx US distribution agreement
PHASE Scientific Exclusive FebriDx® US distribution agreement Summary of anticipated payments Summary of key terms For personal use only With CLIA Milestones Payment timing • Six-year term, with option to extend waiver (US$m) • Exclusive rights to distribute and commercialise FebriDx® Exclusivity fe
Slide 18: FebriDx national reimbursement progress
FebriDx® national reimbursement progress Summary of national reimbursement Key takeaways For personal use only • Medicare / Medicaid: ~25% of payors • Positive reimbursement trends are being observed across multiple regions and care settings • Private insurers: ~75% of payors • At WellStreet Urgent
Slide 19: WellStreet | Urgent Care use case study
WellStreet | Urgent Care use case study Lumos and WellStreet initial agreement to deploy FebriDx® at an urgent care site in Atlanta, handling ~50 respiratory-infection patients per day, with the goal of generating operational and reimbursement data. The successful pilot program underpins a nationwid
Slide 20: FebriDx First - WellStreet clinical protocol
“FebriDx® First” - WellStreet clinical protocol Urgent Care is the focus IF BACTERIAL RESULT For personal use only • If sore throat or exudate present → add Rapid Strep test • Consider antibiotics per clinical judgment STEP 1 STEP 2 IF SEVERE OR ATYPICAL CASE Patient presents with acute PERFORM FEBR
Slide 21: Go-to-market strategy
Go-to-market strategy In addition to Urgent Care, Lumos has also established a go-to-market strategy for Primary Care, as well as an extensive marketing campaign to support the commercialisation of FebriDx For personal use only Market vertical roadmap for Primary Care FebriDx Awareness Campaign • Lu
Slide 22: Facility expansion will underpin demand fulfillment at scale
Facility expansion will underpin demand fulfillment at scale Existing facility expansion to 7,500 square feet to be completed in CY2026, to support anticipated market demand and drive revenue growth. Production establishment, including IQ, OQ and PQ, taking place over 12 months For personal use only
Slide 23: Financials Summary – Quarterly
Financials Summary – Quarterly - In Line with Expectations (Quarterly, US$ in thousands) Revenue ($’000) Revenue Mix Net Cash Generation ($’000)* For personal use only 100% $1,535 $4,822 80% $3,470 $3,363 $2,757 60% $2,625 40% 20% -$1,583 -$1,465 -$1,979 0% Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q3FY26 Q3FY25
Slide 24: Summary
Summary For personal use only ▪1 Lumos YTD FY26 revenue US$10.9m (up 11% yoy) demonstrates strong financial performance ─ Our licensing / IP agreements adds recurring high-margin revenue ▪2 Lumos has a transformational US$317m (A$487m) 6-year distribution deal for FebriDx in the US with PHASE Scient
Slide 25: Capital Raising
For personal use only Capital Raising © Lumos Diagnostics . All rights reserved. 25
Slide 26: SPP equity raising overview
SPP equity raising overview • Eligible Australian and New Zealand shareholders on the Lumos register as at 7:00pm (AEDT) on 26 March 2026 can participate in a non-underwritten SPP of approximately A$2.0 Share million Purchase For personal use only • Lumos reserves the right (in its absolute discreti
Slide 27: Sources and use of funds
Sources and use of funds The proceeds from the capital raising provides balance sheet strength and drive strategic and targeted growth initiatives For personal use only Sources of funds2 A$m1 US$m • Lumos expects to have pro-forma net cash of approximately A$32.93 Capital raising proceeds3 22.0 15.4
Slide 28: SPP equity raising timetable
SPP equity raising timetable Event1 Sydney, Australia time For personal use only SPP record date 7:00pm (AEDT) on Thursday, 26 March Dispatch of SPP offer documents Friday, 10 April SPP opening date Friday, 10 April SPP closing date Friday, 24 April Announcement of SPP participation results Friday,
Slide 29: Share register information
Share register information The share register contained 3,744 shareholders at the SPP record date. The terms of the SPP are identical to those offered to institutional and sophisticated investors, including the free attaching For personal use only options. The majority of our shareholders have the p
Slide 30: Key Risks
For personal use only Key Risks
Slide 31: Key risks
Key risks This section discloses some of the key risks attaching to an investment in Lumos. The Company is subject to risks that are specific to the Company and the Company’s business activities, as well as general risks. Before investing or increasing your investment in Lumos, you should consider w
Slide 32: Key risks (continued)
Key risks (continued) Reliance on Distributors The success of Lumos’ Products business relies on its ability to attract, retain, support and motivate distributors. The loss of, or any significant decrease in business from these distributors may negatively impact For personal use only Lumos’ financia
Slide 33: Key risks (continued)
Key risks (continued) Reimbursement and Coverage Third-party payers, whether U.S. or non-U.S., or governmental or commercial, are developing increasingly sophisticated methods of controlling rising healthcare costs. These include, evaluating the cost- For personal use only effectiveness and economic
Slide 34: International Offer Restrictions
For personal use only International Offer Restrictions © Lumos Diagnostics . All rights reserved. 34
Slide 35: International Offer Restrictions
International Offer Restrictions International Offer Restrictions This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares m
Slide 36: International Offer Restrictions
International Offer Restrictions United Kingdom This document has not been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of Regulation 21 of The Public Offers and Admissions to Trading Regulations 2024 For personal use only (“PO
Slide 37: Glossary
For personal use only Glossary
Slide 38: Glossary
Glossary • ASIC means the Australian Securities and Investments Commission. • IVD means in vitro diagnostics. For personal use only • ASX means ASX Limited ACN 008 624 691 or the financial market known as the 'Australian Securities • MDSAP means Medical Devise Single Audit Program. Exchange' operate
Slide 39: www.lumosdiagnostics.com
For personal use only www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 39
Lumos Diagnostics Holdings — Q3 2026 Earnings Presentation on 6ix